Silence Therapeutics plc priced an underwritten public offering of 12,962,963 American Depositary Shares at $13.50 per ADS, expected to generate approximately $164.0 million in net proceeds. This Capital infusion provides significant funding for the clinical-stage biotechnology company to advance its proprietary siRNA pipeline and accelerate Drug Development initiatives.
Key Highlights
- The offering is expected to generate approximately $164.0 million in net proceeds for the company.
- The company anticipates that the transaction will provide net proceeds of roughly $164.0 million, which will be directed toward advancing its clinical‑stage siRNA programs.
- The terms of the offering were finalized on August 11, 2026, with the underwriters agreeing to purchase the ADSs from Silence Therapeutics at a price of $12.69 per share.
The company anticipates that the transaction will provide net proceeds of roughly $164.0 million, which will be directed toward advancing its clinical‑stage siRNA programs.
Upsized Offering Enhances Financial Position
The terms of the offering were finalized on August 11, 2026, with the underwriters agreeing to purchase the ADSs from Silence Therapeutics at a price of $12.69 per share. This pricing reflects customary Underwriting discounts. The infusion of capital is intended to strengthen the company’s Balance Sheet and extend its runway for Research and Development without immediate reliance on further dilutive financing.
Structure of the ADS Offering
Each ADS represents three ordinary shares of Silence Therapeutics plc, each ordinary share carrying a nominal value of £0.05. This format enables the company to tap U.S. Capital Markets while maintaining a link to its underlying equity. The underwriting agreement contains standard representations, warranties, covenants, and indemnities for both the issuer and the underwriters, ensuring a solid legal framework for the transaction.
Funding the siRNA Pipeline
Silence Therapeutics is a global, clinical‑stage biotech firm focused on leveraging its proprietary siRNA technology platform to develop precision medicines. The capital raised will be allocated to the continued development of its pipeline of siRNA candidates, many of which target diseases with high unmet medical need. By securing this financing, the company seeks to accelerate pre‑clinical and clinical activities, move candidates closer to key trial milestones, and position itself competitively within the broader biotechnology sector.
Closing Timeline and Exhibit References
Upon completion, the anticipated net proceeds of $164.0 million will become available to the company for use in its operational and strategic initiatives. Investors will be watching how the newly obtained resources are deployed across Silence Therapeutics’ development programs, with the next Quarterly Report expected to outline the allocation of funds.






Please wait processing your request...